Objectives: This research investigates the instruments currently available to measure the cancer patient experience of health care. An investigation of the number of instruments, the domains covered by the instruments, and the structure and psychometric performance of instruments is undertaken.
Introduction
Clinical oncology has taken a lead in patient centred care in an effort to better support the often lengthy and arduous cancer patient journey (i.e. diagnosis, treatment, care and ongoing management), as the care journey strongly influences cancer patients" psychological wellbeing and perceived quality of life. 1 What is less clear is the extent to which purpose designed, psychometrically sound measures are available to assess the cancer journey from the patient"s perspective and provide additional confidence to health services in changing cancer care practices based on their results. Researchers suggest that establishing a valid set of patient reported measures reflects further progress towards improving the patient centredness of cancer care. 4 Activity in healthcare quality assessment has grown since the 1960s with the improvement focus of many of the measures continuing to be defined from the perspectives of clinicians and health administrators. 3 More recently, collecting and engaging with patient feedback with the aim of supporting care that is tailored to the requirements of patients is growing in importance. Whether or not these processes of measurement and reporting have caused a marked impact on health outcomes is not clear. Regardless, patient reported measures aimed at facilitating improvement efforts are now formally recognised as key contributors of healthcare quality, alongside safety and clinical effectiveness. 4 The use of patient reported measures is often an attempt to identify the degree to which health care is "patient-centred", the key features of which are defined as: identifying and respecting patient choices; informing and involving patients; involving patients in health care processes;
treating patients with dignity; ensuring health care processes match patient needs; access to relevant health information; and continuity of care. 5 To ensure translation of these features into care processes, patient experience data must be sufficiently and accurately captured. Until recently, patient experience and other complex subjective patient reported themes were considered beyond the scope of accurate measurement. However a growing body of evidence has now shown that aspects of care from the patient"s perspective can be measured in purpose designed and tested instruments, providing convenient numerical summaries of features of the healthcare journey that patients consider important. preferences; experiences; outcomes; and/or satisfaction with care. Collecting and crossreferencing information across these domains provides a rich platform on which care might be transformed and more information provided on what is important to patients than would otherwise be available if each area was measured in isolation. 6 When examining instruments that measure what matters to patients, one of the most important considerations is establishing the fidelity of the instrument. Numerous properties are tested to
give confidence that instruments are measuring what they are designed to measure. These properties include: reliability (i.e. produces consistent results in repeated measurements of the same circumstance or event); validity (i.e. the measure is related to the dimension it is supposed to assess (i.e. face validity); whether it covers the whole dimension it is supposed to assess (i.e. content validity); and is it related to other measures evaluating the same dimension (i.e. construct validity).
7
Aim
This work is part of a larger project investigating the cancer patient experience field overall. 8 The aim of this inquiry is to investigate the instruments currently available to specifically measure the cancer patient experience of health care. An investigation of the number of instruments, the domains covered by the instruments, and the structure and psychometric performance of Twenty-six peer-reviewed research papers, which met the inclusion criteria and were of sufficient quality, were analysed. The assessed psychometric measurement properties of the cancer patient experience instruments in the studies were tabled (i.e. responsiveness, internal consistency, content validity, criterion validity, construct validity, interpretability, reproducibility and floor and ceiling effects) 14 and are available in Table 2 . A summary of included studies is available in Table 3 . An assessment of quality of academic papers was undertaken using the Critical Appraisal Skills Programme. 15 The Critical Appraisal Skills Programme (CASP) grew out of the work of the UK Critical Appraisal Skills Project in Oxford. The programme aims to support the appraisal of scientific evidence. Underpinned by a number of expert developed assessment checklists, CASP appraises the broad issues that need to be considered systematically when appraising research including considering if research is unbiased, results valid and an assessment of the importance of the results. 16 Two reviewers independently assessed each study before collective agreement was determined. 
Results

Instrument development and structure
The majority of identified instruments across the included studies were originally designed for the oncology field. The newly developed instruments and those adapted from existing tools underwent a staged process of development which commonly included the generation of preliminary items, often using cancer patient interviews and/or focus groups, consultation with providers, and/or reviews of the literature, with some papers also reviewing specific evidenced 11 based cancer management guidelines. Pilot testing to support readability, interpretability/clarity and/or content validity was then frequently undertaken. Larger studies were then conducted to field test the final agreed item set and assess some or all of their psychometric properties. All but one of the instruments examined in the studies was based on a multidimensional framework with the number of items (i.e. patient questions) ranging from 15 to 152, within 1 to 15 different domains (i.e. categories).
Psychometric performance
The number of instruments assessing cancer patient experience that have sound psychometric
properties across items was found to be low, a finding also reported in reviews of patient reported measures overall. The properties least tested were test-retest reliability, construct, convergent and discriminant validity, scale variability (floor/ceiling effects) and interpretability.
The psychometric measurement properties tested in each instrument evaluated in this review can be found in 
Discussion
It is now generally recognised that there is a need for rigorous approaches to obtain patients' views on the care they receive. As a result, much effort has, and continues to be, committed to developing and evaluating survey measures that reflect healthcare experiences. Sound psychometric properties support an understanding of the "if" and "how well" an instrument measures cancer patient experience. Test-retest reliability was one property least tested in the studies examined. This potentially means that the measures examined may not provide similar results if administered at different times, even with the same cohort. The complexity of the cancer journey is often reflected in an unpredictable care routine, which emphasises the need for consistency in results of cancer patient experience measurements if improvement requirements are to be accurately identified and acted upon. Language and cultural issues have also been
shown to affect test-retest reliability, making the direct implementation of instruments developed in other countries problematic. 29 Construct validity, which reflects the ability of the instruments to measure cancer patient experience, was also inadequately tested across the studies examined in this review. If instruments cannot provide confidence in their ability to measure cancer patient experience, they are much less likely to be applied in practice. A further gap in the testing of instruments was the responsiveness of the instruments to change and/or how well they capture variances in cancer care processes. The relational aspects of the different cancer patient experience measures are also largely unidentified (e.g. do some measures inform, augment or diminish others etc.). Poorly understood from existing studies is also the extent to which the measures may be able to capture differences in cancer care across care environments and time frames. 
Limitations of the Review
The central limitation of this review of cancer patient experience measures is the potential noninclusion of relevant articles and unpublished material. Our search strategy relied on key words assigned by authors and may have missed studies that are relevant to the review but were not identified. Another limitation is the assessment of psychometric properties which was based on individual study acknowledgement of testing, hence the quality of psychometric properties of instruments was not identified which may mean an overestimation of the psychometric performance of instruments or items therein. Finally, any cancer patient experience measures or items within existing quality of life instruments were not included in this review leading to a potential underestimation of available cancer patient experience measures.
Conclusion
Cancer patient experience measures are used, normally alongside other cancer patient reported measures, as indicators of quality cancer care. The currently available studies that inform the field of cancer patient experience measures are of different sample sizes, achieve different  Three focus group discussions to determine items for inclusion in pilot questionnaire, 27 patients (n = 11, n = 9 and n = 7).  Pilot oral questionnaire completed by 731 women (response 63%) filled in the experience survey. Selected from claims data of four health insurance companies.  Participants had various stages of diagnosis and disease progression; must have had breast care within previous 24 months Aim: Develop an instrument to assess quality of care in breast cancer patients.
 Cancer patients" participants across a range of treatment modalities recruited from five hospitals.  Focus groups followed by concept mapping to determine relevant items for inclusion. 72 participants across eight focus groups. 67 participants across the six concept map meetings. Focus group participants had curative surgery in the previous 15 months; concept mapping participants had surgery in the previous 12 months.  Software programme based on multidimensional scaling and hierarchical cluster analysis used for analysis of the concept map data. This resulted in visual displays ("concept maps") depicting relationships in clusters between the aspects that had been grouped by the participants. 
